OBJECTIVE: To ascertain the impact of treatment with citalopram on irritability, apathy, delusions, and hallucinations in nondepressed behaviorally disturbed Alzheimer's disease (AD) patients. METHOD: This was a retrospective analysis of data from the 36-week Clinical Antipsychotic Trials of Intervention Effectiveness in Alzheimer's Disease in which patients with probable AD (diagnosed according to criteria of the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association [NINCDS/ADRDA]) were treated in a naturalistic manner. Scores were compared on the irritability, apathy, delusions, and hallucinations subscales of the Neuropsychiatric Inventory. The trial was conducted between April 2001 and November 2004. RESULTS: Of the 421 patients enrolled, 44 were started onplacebo and were later randomly assigned to citalopram treatment. There were data available for 34 subjects who tookplacebo for at least 14 days. In this group, there was a 60% reduction in irritability and apathy scores, no effect on scores for delusions, and a clinically insignificant drop in scores for hallucinations. CONCLUSIONS: The use of citalopram was associated with greatly reduced irritability without sedation in a group of behaviorally disturbed patients with AD. Copyright 2009 Physicians Postgraduate Press, Inc.
RCT Entities:
OBJECTIVE: To ascertain the impact of treatment with citalopram on irritability, apathy, delusions, and hallucinations in nondepressed behaviorally disturbed Alzheimer's disease (AD) patients. METHOD: This was a retrospective analysis of data from the 36-week Clinical Antipsychotic Trials of Intervention Effectiveness in Alzheimer's Disease in which patients with probable AD (diagnosed according to criteria of the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association [NINCDS/ADRDA]) were treated in a naturalistic manner. Scores were compared on the irritability, apathy, delusions, and hallucinations subscales of the Neuropsychiatric Inventory. The trial was conducted between April 2001 and November 2004. RESULTS: Of the 421 patients enrolled, 44 were started on placebo and were later randomly assigned to citalopram treatment. There were data available for 34 subjects who took placebo for at least 14 days. In this group, there was a 60% reduction in irritability and apathy scores, no effect on scores for delusions, and a clinically insignificant drop in scores for hallucinations. CONCLUSIONS: The use of citalopram was associated with greatly reduced irritability without sedation in a group of behaviorally disturbed patients with AD. Copyright 2009 Physicians Postgraduate Press, Inc.
Authors: Lon S Schneider; Pierre N Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; T Scott Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: B G Pollock; B H Mulsant; R Sweet; L D Burgio; M A Kirshner; K Shuster; J Rosen Journal: Am J Geriatr Psychiatry Date: 1997 Impact factor: 4.105
Authors: Jeffrey L Cummings; Rochelle E Tractenberg; Anthony Gamst; Linda Teri; Donna Masterman; Leon J Thal Journal: Curr Alzheimer Res Date: 2004-11 Impact factor: 3.498
Authors: Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong Journal: Neurosci Lett Date: 2019-04-01 Impact factor: 3.046
Authors: Jeremy G Stone; Gemma Casadesus; Kasia Gustaw-Rothenberg; Sandra L Siedlak; Xinglong Wang; Xiongwei Zhu; George Perry; Rudy J Castellani; Mark A Smith Journal: Ther Adv Chronic Dis Date: 2011-01-01 Impact factor: 5.091
Authors: Shefali Chaudhary; Simon Zhornitsky; Herta H Chao; Christopher H van Dyck; Chiang-Shan R Li Journal: Am J Alzheimers Dis Other Demen Date: 2022 Jan-Dec Impact factor: 2.632